Du är här


Bionor Pharma ASA: Notice of extraordinary general meeting 11 February 2016



Notice of extraordinary general meeting 11 February 2016

(Oslo, Norway, 21 January 2016) Bionor Pharma ASA (OSE: BIONOR) will conduct
an extraordinary general meeting (EGM) on 11 February 2016 at 12:00 CET at
Hotel Continental in Theatersal 1, Stortingsgaten 24/26, Oslo, Norway.

Notice of the extraordinary general meeting is attached hereto and includes
detailed registration and proxy instructions for the EGM as well as full
Board proposals and background information.

Please also refer to stock exchange announcement issued earlier today
regarding the launched private placement, "Bionor Pharma contemplates private
placement of new shares

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information

Cecilie Grue, Director Legal Affairs, +47 99162486, cg@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine
Vacc-4x in combination with other medicines toward a functional HIV cure. The
company believes it has first mover potential based on clinical results to
date and early adoption of now recognized clinical strategy. In December
2015, Bionor announced that the HIV 'Shock&Kill' trial REDUC with Vacc-4x and
romidepsin successfully met its primary endpoint by significantly reducing
latent HIV reservoir and further demonstrated control of viral load. Bionor
is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may
lead to a major value inflection point and partnering opportunities. Bionor
currently retains full ownership rights to Vacc-4x, i.e., the upside
potential from partnering or licensing remains with the company. Bionor is
based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New
York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about
Bionor is available atwww.bionorpharma.com.

Notice of EGM 11 February 2016


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.